Skip to main content
S 3780 116th Congress Senate Health Chemical and biological weapons Congressional oversight Department of Health and Human Services Drug safety, medical device, and laboratory regulation Emergency medical services and trauma care Executive agency funding and structure Federal officials Government lending and loan guarantees Health programs administration and funding Health technology, devices, supplies Licensing and registrations Manufacturing Military procurement, research, weapons development Public contracts and procurement Strategic materials and reserves Terrorism

HOME Act

Introduced: May 20, 2020 Introduced by: Peters, Gary C. Democratic · Michigan See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 20, 2020
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
May 20, 2020
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Help Onshore Manufacturing Efficiencies for Drugs and Devices Act or the HOME Act

This bill contains provisions related to critical drugs and medical devices.

The bill establishes within the Department of Health and Human Services (HHS) the Center for Domestic Advanced Manufacturing of Critical Drugs and Devices. The center shall establish and implement a program to provide grants and forgivable loans to support investment in advanced manufacturing for the domestic production of critical drugs, medical devices, and active pharmaceutical ingredients.

Furthermore, a supplemental application for a critical drug approved by the Food and Drug Administration (FDA) may receive expedited review if, among other requirements, the applicant plans to produce the drug domestically after the approval of the supplemental application. (A supplemental application generally involves a change, such as a manufacturing change, to an existing application for FDA approval.)

The bill also authorizes HHS and the Department of Defense to enter into multiyear high-volume contracts to purchase critical drugs and medical devices.

What's happening now May 20, 2020

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
Cite this page click to expand
APA
U.S. Congress. (2026). S. 3780: HOME Act. 116th Congress. Open America. https://openamerica.io/bill/116-S-3780/
MLA
"S. 3780: HOME Act." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-S-3780/.
Bluebook (legal)
S. 3780, 116th Cong. (2026), https://openamerica.io/bill/116-S-3780/.
Markdown link
[S. 3780: HOME Act](https://openamerica.io/bill/116-S-3780/)
Report a problem